Mon, Jun 17, 8:28 PM (82 days ago)
Exicure, Inc. reported an operating loss of $836,000 for Q1 2024, significantly reduced from $4.5 million in Q1 2023, mainly due to the suspension of research and development activities and reduced general and administrative expenses. The company generated $500,000 in revenue from a licensing agreement related to its historical drug candidate, cavrotolimod. Cash and cash equivalents decreased from $816,000 at year-end 2023 to $366,000 as of March 31, 2024. Exicure's liquidity remains critical, with substantial additional funding needed in the near term to continue operations and strategic alternatives exploration. The company has received a delisting determination from Nasdaq and is appealing.